<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403115</url>
  </required_header>
  <id_info>
    <org_study_id>SLE1</org_study_id>
    <nct_id>NCT02403115</nct_id>
  </id_info>
  <brief_title>Prediction of Outcome of Lupus Nephritis</brief_title>
  <official_title>Validation of the Assay of Circulating Antibodies Against Glomerular Neo-autoantigens as a Surrogate Biomarker of the Development of Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Giannina Gaslini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Giannina Gaslini</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to clarify the mechanisms involved in the formation and
      glomerular deposition of immune complexes in lupus nephritis.

      The determination of an antibody pattern specific for systemic lupus erythematosus and lupus
      nephritis may also have a role in predicting disease progression in patients with systemic
      lupus erythematosus without renal impairment. As for the patients enrolled in the study, the
      determination of their antibody patterns may contribute to a more targeted and personalized
      treatment, allowing a prediction of disease progression and the introduction of early
      targeted treatments, in order to block the onset and/or progression of renal damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective multicenter study on the validity of levels of circulating antibodies to
      glomerular neo-autoantigens (alpha-enolase and annexin AI) and implantable antigens
      (anti-DNA, histone, istone3, istone4, C1q) as a surrogate biomarker for the diagnosis of
      lupus nephritis.

      The study will involve the collection of serum from patients with lupus nephritis at onset
      and during subsequent follow-up at 6, 12, 24 and 36 months for the titration of circulating
      autoantibodies.

      As a control the investigators will use the sera of patients with systemic lupus
      erythematosus without nephropathy, collected at the same time intervals.

      The investigators will also assess the antibody positivity in groups of patients with
      rheumatologic disease similar to lupus (rheumatoid arthritis) and in patients with autoimmune
      nephropathy without extrarenal clinical signs.

      Regarding patients with systemic lupus erythematosus the investigators will collect sera of
      both incident and prevalent patients in order to monitor changes in antibody levels in
      conjunction with the development of renal disease.

      Clinical tests (renal function, complete blood count, C reactive protein (CRP), ANA, native
      DNA (nDNA), urine analysis) will be performed at 6, 12, 24 and 36 months and the surplus of
      blood samples will be used to create the serum bank of the study.

      Samples will be collected in the pediatric nephrology of Giannina Gaslini Children Hospital,
      Genoa (coordinator centre) and in 5 rheumatological (Genoa, Pisa, Pavia, Padova, Brescia) and
      6 nephrological (Milan, Genoa, Parma, Brescia, Bologna and Reggio Emilia) italian adults
      departments .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Proteinuria at 12, 24 and 36 months</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>proteinuria measured on a 24-hour urine collection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>36 months</time_frame>
    <description>estimated glomerular filtration rate (eGFR) measured according to Revised Bedside Schwartz Formula (4-17 years old patients) or CKD-EPI Creatinine 2009 Equation (18-64 years old patients)</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Lupus Nephritis</arm_group_label>
    <description>Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Incident SLE without nephritis</arm_group_label>
    <description>Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies, in order to evaluate the presence of nephritic manifestations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevalent SLE without nephritis</arm_group_label>
    <description>Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <description>Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Membranous glomerulonephritis</arm_group_label>
    <description>Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to exclude secondary forms of the disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum collection</intervention_name>
    <description>Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study</description>
    <arm_group_label>Lupus Nephritis</arm_group_label>
    <arm_group_label>Incident SLE without nephritis</arm_group_label>
    <arm_group_label>Prevalent SLE without nephritis</arm_group_label>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <arm_group_label>Membranous glomerulonephritis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  250 patients with newly diagnosed lupus nephritis (stage I-VI according to WHO
             classification). First serum will be collected at the time of renal biopsy (study
             group).

          -  250 patients with incident or prevalent systemic lupus erythematosus (according to ARA
             criteria) and no signs of nephropathy (control group).

          -  50 patients with rheumatoid arthritis (according to ARA criteria), without documented
             nephropathy (control group)

          -  250 patients with histological diagnosis of membranous nephropathy (control group).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 4 and 65 years

          -  Diagnosis of lupus nephritis-systemic lupus erythematosus (systemic lupus
             erythematosus, rheumatoid arthritis and membranous nephropathy for controls)

          -  Informed consent

        Exclusion Criteria:

          -  Severe infections in place

          -  Malignancies of any current or history

          -  Chronic hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) positive

          -  Breast-feeding or pregnant

          -  Known hypersensitivity to drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gian Marco Ghiggeri, MD</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS Giannina Gaslini, Genoa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gian Marco Ghiggeri, MD</last_name>
    <phone>0039 010 56362419</phone>
    <email>gmarcoghiggeri@ospedale-gaslini.ge.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Giannina Gaslini Children Hospital</name>
      <address>
        <city>Genoa</city>
        <state>Italy/GE</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Marco Ghiggeri, MD</last_name>
      <phone>0039 010 5636 2419</phone>
      <email>gmarcoghiggeri@ospedale-gaslini.ge.it</email>
    </contact>
    <investigator>
      <last_name>Gian Marco Ghiggeri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Bonanni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999 Feb;10(2):413-24. Review.</citation>
    <PMID>10215343</PMID>
  </reference>
  <reference>
    <citation>Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun. 2014 Feb-Mar;48-49:10-3. doi: 10.1016/j.jaut.2014.01.004. Epub 2014 Jan 21. Review.</citation>
    <PMID>24461385</PMID>
  </reference>
  <reference>
    <citation>Madaio MP. The relevance of antigen binding to the pathogenicity of lupus autoantibodies. Kidney Int. 2012 Jul;82(2):125-7. doi: 10.1038/ki.2012.159.</citation>
    <PMID>22743561</PMID>
  </reference>
  <reference>
    <citation>Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus. 2005;14(1):19-24. Review.</citation>
    <PMID>15732283</PMID>
  </reference>
  <reference>
    <citation>Bagavant H, Fu SM. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol. 2009 Sep;21(5):489-94. doi: 10.1097/BOR.0b013e32832efff1. Review.</citation>
    <PMID>19584729</PMID>
  </reference>
  <reference>
    <citation>Hanrotel-Saliou C, Segalen I, Le Meur Y, Youinou P, Renaudineau Y. Glomerular antibodies in lupus nephritis. Clin Rev Allergy Immunol. 2011 Jun;40(3):151-8. doi: 10.1007/s12016-010-8204-4. Review.</citation>
    <PMID>20414746</PMID>
  </reference>
  <reference>
    <citation>Kramers C, Hylkema MN, van Bruggen MC, van de Lagemaat R, Dijkman HB, Assmann KJ, Smeenk RJ, Berden JH. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest. 1994 Aug;94(2):568-77.</citation>
    <PMID>8040312</PMID>
  </reference>
  <results_reference>
    <citation>Bruschi M, Galetti M, Sinico RA, Moroni G, Bonanni A, Radice A, Tincani A, Pratesi F, Migliorini P, Murtas C, Franceschini F, Trezzi B, Brunini F, Gatti R, Tardanico R, Barbano G, Piaggio G, Messa P, Ravani P, Scolari F, Candiano G, Martini A, Allegri L, Ghiggeri GM. Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens. J Am Soc Nephrol. 2015 Aug;26(8):1905-24. doi: 10.1681/ASN.2014050493. Epub 2014 Nov 14.</citation>
    <PMID>25398787</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruschi M, Sinico RA, Moroni G, Pratesi F, Migliorini P, Galetti M, Murtas C, Tincani A, Madaio M, Radice A, Franceschini F, Trezzi B, Bianchi L, Giallongo A, Gatti R, Tardanico R, Scaloni A, D'Ambrosio C, Carnevali ML, Messa P, Ravani P, Barbano G, Bianco B, Bonanni A, Scolari F, Martini A, Candiano G, Allegri L, Ghiggeri GM. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: Î±-enolase and annexin AI. J Am Soc Nephrol. 2014 Nov;25(11):2483-98. doi: 10.1681/ASN.2013090987. Epub 2014 May 1.</citation>
    <PMID>24790181</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Giannina Gaslini</investigator_affiliation>
    <investigator_full_name>Gian Marco Ghiggeri MD, PhD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

